Liver Disease News and Research

RSS

The liver is one of the largest solid organs of the body. It is located in the upper right part of the abdomen. Most of the organ lies under cover of the rib cage.

Teva to present abstracts on AZILECT at MDS meeting

Teva Pharmaceutical Industries Ltd. announced today that a number of abstracts will be presented during the 17th Annual International Congress of Parkinson's Disease and Movement Disorders in Sydney, Australia, June 16-20, 2013, also known as the Movement Disorders Society.

15 Jun 2013

Researchers at Albert Einstein College of Medicine convene one-day conference on Jewish genetics

Today, researchers at Albert Einstein College of Medicine of Yeshiva University convened a one-day conference on Jewish genetics designed to encourage collaboration and advance the field of research.

14 Jun 2013

SLU professor to study treatment services offered to young mothers and children

Through a $300,000 grant from Administration of Children and Families, part of Department of Health and Human Services, Debra Zand, Ph.D., associate professor of pediatrics at Saint Louis University, will study treatment services offered by a local community provider to St. Louis area women who abuse illegal substances, and for their infants and toddlers.

14 Jun 2013

Mount Sinai researchers produce cells that resemble hematopoietic stem cells

By transferring four genes into mouse fibroblast cells, researchers at the Icahn School of Medicine at Mount Sinai have produced cells that resemble hematopoietic stem cells, which produce millions of new blood cells in the human body every day.

14 Jun 2013

Constella® (linaclotide), for the symptomatic treatment of Irritable Bowel Syndrome with Constipation (IBS-C), is now available in Germany, UK and Nordic countries

Almirall, S.A. (ALM:MC) and Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced the launch of Constella® (linaclotide 290mcg capsules once daily), the first approved prescription therapy in a new class of treatments for adults suffering from moderate to severe IBS-C,(1) in Europe. Constella® is now available in Germany, the UK and Nordic countries and is expected to be launched in several other European countries in 2013.

13 Jun 2013

Investigational all-oral interferon-free combination from Boehringer Ingelheim achieves 95% viral cure rates in genotype-1b hepatitis C patients

New data from Boehringer Ingelheim’s interferon-free SOUND-C3 study were presented during the APASL Liver Week in Singapore. The Phase IIb study investigated the efficacy and safety of faldaprevir+ and deleobuvir+ (BI 207127) plus ribavirin in treatment-naïve patients with genotype-1b (GT-1b) hepatitis C virus (HCV),1 one of the most common types of HCV globally.2

13 Jun 2013

Few cups of hot cocoa may help obese people better control inflammation-related diseases

A few cups of hot cocoa may not only fight off the chill of a winter's day, but they could also help obese people better control inflammation-related diseases, such as diabetes, according to Penn State researchers.

13 Jun 2013

Study shows iron-uptake receptor plays a role in HCV infection

Hepatitis C virus (HCV) infects more than 170 million people worldwide. Approximately 80 percent of infections lead to chronic illness including fibrosis, cirrhosis, cancer and also hepatic iron overload.

11 Jun 2013

BioLineRx signs out-licensing agreement with CTTQ to develop, commercialize Hepatitis C drug

BioLineRx, a biopharmaceutical development company, announced today that it has signed an out-licensing agreement with Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd., the leading Chinese pharmaceutical company in the liver disease therapeutic area, for the development and commercialization of BL-8030, an orally available treatment for the Hepatitis C virus.

10 Jun 2013

Discovery highlights protective role of liver enzyme in treating jaundice

Helping to protect newborns and older patients against more severe effects of jaundice is the hope of University of Guelph researchers, who have shown how a liver enzyme protects cells from damage caused by the condition.

10 Jun 2013

Liver regeneration using cell therapy may be possible, study suggests

Liver transplantation is the mainstay of treatment for patients with end-stage liver disease, the 12th leading cause of death in the United States, but new research from the Icahn School of Medicine at Mount Sinai, published in the online journal Cell Stem Cell today, suggests that it may one day become possible to regenerate a liver using cell therapy in patients with liver disease.

10 Jun 2013

Low levels of vitamin D associated with high levels of hepatitis B virus replication

Researchers from Germany have found that low levels of vitamin D are associated with high levels of hepatitis B virus replication. Findings published online in Hepatology, a journal of the American Association for the Study of Liver Diseases, suggest seasonal fluctuations in vitamin D and HBV levels point to a link in these variables among patients with chronic HBV.

6 Jun 2013

Doctors should conduct frail screening to prevent bad outcomes

Everyone older than 70 should be checked for frailty, a condition that is both easily treated and potentially deadly, according to an article by representatives from six major international and U.S. medical organizations.

5 Jun 2013

EU funds d-LIVER project to help people suffering from liver disease

The EU has provided funding for the d-LIVER project, in which researchers from several countries will work on a number of measures to help people suffering from liver disease.

5 Jun 2013

CWRU nursing school receives NINR grant to support palliative care

Medical advancements that extend the lives of patients with cancer, heart failure and other serious chronic diseases have created another need: more clinicians skilled in specialized care for people with terminal illnesses.

4 Jun 2013

Interval between pregnancies: A golden window for obese women to lose weight

The time between pregnancies is a golden window for obese women to lose weight, a Saint Louis University study finds.

4 Jun 2013

Australia's PBAC recommends use of XIFAXAN 550 mg for hepatic encephalopathy

Norgine today announced that the Australian assessment body the Pharmaceutical Benefits Advisory Committee has recommended the use of XIFAXAN 550 mg in the prevention of the recurrence of hepatic encephalopathy where other treatments have failed or are contraindicated; a potentially life-threatening neuropsychiatric condition associated with liver disease.

24 May 2013